On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > LATEST
LATEST
-
ORGANIZATION Pharma Groups Reiterate “No” to Broader CEA Use, Huge-Seller and Spillover Rules: Joint Statement
December 17, 2025
-
REGULATORY Truqap Braced for Price Cut after Cost-Effectiveness Assessment
December 11, 2025
-
REGULATORY MOF Panel Submits Budget Proposal, Urges Wider CEA Use and More Frequent Re-Pricing
December 3, 2025
-
COMMENTARY MOF Autumn Proposals Signal a Shift from Drug Pricing to Cost-Sharing Reform
November 17, 2025
-
REGULATORY Elrexfio to Escape CEA-Based Price Tweak, Analysis to Resume for Paxlovid
November 17, 2025
-
REGULATORY Industry Opposes Deeper CEA Price Cuts for “Cost-Increase” Products
November 13, 2025
-
REGULATORY MOF Pushes Stronger Use of CEA for Pricy Meds towards FY2026 Budget
November 11, 2025
-
REGULATORY Reblozyl to Face 8% Cut, Vyloy 4% in February: CEA Adjustment
November 6, 2025
-
REGULATORY MHLW Outlines 4 Key Themes for 2026 Reform, Eyes OTC-Like Meds, CEA for Efficiency
October 24, 2025
-
REGULATORY Japan to Clarify Criteria for Upward Price Adjustments under CEA Scheme
October 16, 2025
-
REGULATORY Deeper CEA Price Cuts Mooted for “Cost Increase” Products: FY2026 Reform Debate
October 16, 2025
-
REGULATORY Vyloy Braced for Price Cut after Cost-Effectiveness Assessment
October 16, 2025
-
REGULATORY Rift Surfaces over What Constitutes “Objective Review” of CEA
September 29, 2025
-
REGULATORY Reblozyl Faces Price Cut after Cost-Effectiveness Assessment
September 11, 2025
-
REGULATORY Industry Urges “Objective Review First” for CEA Reform; Payers Push for Expansion
August 7, 2025
-
REGULATORY Chuikyo Rules Out Long-Term Care Costs in Leqembi CEA, Confirms Price Cut
August 7, 2025
-
REGULATORY Wegovy, Leqvio, Phozevel to Face CEA-Linked Price Cuts in November
August 7, 2025
-
REGULATORY Japan Begins FY2026 CEA Reform Talks, Re-Designation after Market Expansion Up for Debate
July 17, 2025
-
REGULATORY Leqembi Likely to Face 15% Price Cut Under Special CEA Rule
July 10, 2025
-
ORGANIZATION Pharma Labor Platform Calls for Inflation-Responsive Drug Pricing Reforms, Opposes CEA Expansion
July 3, 2025
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…